ライフサイエンスコーパス: nucleotidase

1 th the AAA-ATPase PAN (proteasome-activating nucleotidase).

2 tions in the same gene, NT5C2, encoding a 5'-nucleotidase.

3 pecifically blocked by parasite secretory 5'-nucleotidase.

4 rom ischemic neurologic injury by soluble 5'-nucleotidase.

5 ated by treatment of WT mice with soluble 5'-nucleotidase.

6 suppresses pain by functioning as an ecto-5'-nucleotidase.

7 mediated by selective inhibition of ecto-5'-nucleotidase.

8 potential targets of zinc other than ecto-5'-nucleotidase.

9 tional change in the secreted, soluble human nucleotidase.

10 F0115), referred to as proteasome-activating nucleotidase.

11 r agonists or reconstitution with soluble 5'-nucleotidase.

12 ctions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

13 with inhibition of SAH hydrolase but not 5'-nucleotidase.

14 rward ADP-mediated inhibition of the ecto-5'-nucleotidase.

15 ere all significantly reduced by blocking 5'-nucleotidase.

16 indicating significant breakdown by soluble nucleotidases.

17 from released ATP through a cascade of ecto-nucleotidases.

18 lular synapses, within which we localize the nucleotidases.

19 PAP) phosphatase (gPAPP) and Bisphosphate 3'-nucleotidase 1 (Bpnt1).

20 the amount of transcript of Ca(2+)-activated nucleotidase 1 (CANT1), an endoplasmic reticulum (ER)-Go

21 Human soluble calcium-activated nucleotidase 1 (hSCAN-1) is the human homologue of solub

22 Human soluble calcium-activated nucleotidase 1 (hSCAN-1) represents a new family of apyr

23 arasites, including Pf, have an IMP-specific-nucleotidase 1 (ISN1).

24 pe 1 and identified CANT1 (calcium activated nucleotidase 1) mutations as responsible for DBQD type 1

25 hSCAN-1 for human soluble calcium-activated nucleotidase-1, was expressed in bacteria, refolded from

26 ysis revealed that Mup44 is the cytosolic 5'-nucleotidase 1A (cN1A).

27 ntire human proteome identified cytosolic 5'-nucleotidase 1A (cN1A; NT5C1A) as the likely 43 kDa IBM

28 Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing mode

29 escription of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially im

30 We demonstrate that soluble 5'-nucleotidase (5'-NT) and alkaline phosphatase (AP) media

31 uster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

32 hat purified, recombinant human cytosolic 5'-nucleotidases (5'-NTs) CN-II and CN-III, but not CN-IA,

33 enzymatic activity assays indicated that 5'-nucleotidase (5NT), rather than AP, was responsible for

34 nce factor, which we termed streptococcal 5'-nucleotidase A (S5nA).

35 se estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are f

36 bcellular location and the mechanism of ecto-nucleotidase activation, we expressed human NTPDase3 in

37 of several apyrase conserved regions for the nucleotidase activities of the NTPDases.

38 n X-100 detergent inhibition of Ca-dependent nucleotidase activities while greatly attenuating Triton

39 tyrosine resulted in dramatically increased nucleotidase activities, while mutagenesis of aspartic a

40 ting Triton X-100 inhibition of Mg-dependent nucleotidase activities.

41 se6-transfected COS-1 cells were assayed for nucleotidase activities.

42 Given the high nucleotidase activity and apparently normal receptor sig

43 dentified a novel S. pyogenes enzyme with 5'-nucleotidase activity and immune evasion properties.

44 n had small, but detectable reduction in its nucleotidase activity and nucleotide binding affinity.

45 Collectively, our data support a role for 3'-nucleotidase activity and PAP metabolism in aspects of l

46 ically, NT5C2 mutant proteins have increased nucleotidase activity as a result of altered activating

47 These results indicate that the lack of ecto-nucleotidase activity exhibited by NTPDase2 beta and -2

48 NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance

49 pounds induced a strong inhibition of the 5'-nucleotidase activity in vitro, and the most potent ones

50 zymes possess nicotinamide mononucleotide 5'-nucleotidase activity in vitro.

51 The NudP ecto-5'-nucleotidase activity is reminiscent of the reactions pe

52 ADPase activity, further indicating that the nucleotidase activity of CAN is linked to its quaternary

53 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown to

54 d-lineage cells is attributed in part to the nucleotidase activity of the SAM-domain and HD-domain co

55 ant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucleoside 5

56 not occur in bacteria are not necessary for nucleotidase activity or proper folding of this human ap

57 ght responses via its 3'(2'),5'-bisphosphate nucleotidase activity rather than its inositol polyphosp

58 hange in the divalent cation requirement for nucleotidase activity relative to the wild-type and the

59 In COS-7 cells, 5'-nucleotidase activity was not rate-limiting for inosine

60 Accordingly, exogenous nucleotidase activity was required to fully preserve P2X

61 We show that cNIII-like also displays 5' nucleotidase activity with a high affinity for m(7)GMP.

62 cken liver ecto-ATPDase cDNA express an ecto-nucleotidase activity with characteristics similar to th

63 ther, our studies suggest that CD39 and CD73 nucleotidase activity within junctional spaces can explo

64 the relationship between the FRY1-associated nucleotidase activity, a step in the pathway for sulfur

65 mma, produced a protein completely devoid of nucleotidase activity, while mutation of Asn443 to Asp r

66 ate-1-phosphatase and 3'(2'),5'-bisphosphate nucleotidase activity.

67 ut how these factors control the kinetics of nucleotidase activity.

68 nformational change in hSCAN-1 necessary for nucleotidase activity.

69 ine 271 resulted in enzymes with very little nucleotidase activity.

70 l-nucleotide substrate complex necessary for nucleotidase activity.

71 thyroxine concentrations and mononuclear 5'-nucleotidase activity.

72 e recombinant and native proteins possess 5'-nucleotidase activity; hence, the protein has been calle

73 , thus raising the question whether the ecto-nucleotidases affect the ATP-dependent processes in thes

74 th bleomycin and supplemented with exogenous nucleotidase also exhibited reduced inflammation.

75 thylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+) currents

76 king A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellular AMP

77 tudy tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conversion o

78 NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosine from e

79 id rafts marked by GPI-anchored proteins (5' nucleotidase and folate receptor).

80 Here we report a role for 3'-nucleotidase and its substrate, 3'-phosphoadenosine 5'-p

81 HD-domain phosphohydrolases have nucleotidase and phosphodiesterase activities and play i

82 SNPs at the 5'-nucleotidase and xanthine oxidase genes influence the ri

83 displayed high selectivity versus other ecto-nucleotidases and ADP-activated P2Y receptors.

84 asomes associated with proteasome-activating nucleotidases and membrane-associated Lon proteases.

85 peptide, vascular endothelial growth factor, nucleotidases and nucleases, nerve growth factor, and L-

86 w that NR is constantly produced by multiple nucleotidases and that the intracellular NR pools are li

87 e following secreted exoenzymes: apyrase, 5'-nucleotidase, and adenosine deaminase.

88 adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adenosine rec

89 n phosphatases, purple acid phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

90 e, protein serine/threonine phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

91 oblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

92 , initially classified as an IMP-specific 5'-nucleotidase, and Sdt1, initially classified as a pyrimi

93 s unrelated in sequence to more well-studied nucleotidases, and very little is known about the enzyma

94 g treatment with a high concentration of the nucleotidase apyrase (17 +/- 5 pA/pF for 10 IU/ml and 11

95 oliferation were induced by the soluble ecto-nucleotidase apyrase and the P2 receptor inhibitor suram

96 Both these ecto-nucleotidases are expressed by Presynaptic cells, as sho

97 secretory pathway, the active sites of ecto-nucleotidases are located in the lumen of vesicular comp

98 dt1, initially classified as a pyrimidine 5'-nucleotidase, are additionally responsible for dephospho

99 enzymatic activation of hSCAN-1 detected by nucleotidase assay.

100 muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

101 Bisphosphate 3'-nucleotidase (BPNT-1) is a lithium-sensitive phosphatase

102 Bisphosphate 3'-nucleotidase (BPNT1 in mammals and Met22/Hal2 in yeast)

103 ssion of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD39L1), in

104 tic activity and biological function in this nucleotidase by mutating isoleucine 170, which is locate

105 Human calcium-activated nucleotidase (CAN) exists as both a membrane-bound form

106 analysis demonstrated that NBD1 is a general nucleotidase capable of hydrolysis of ATP, CTP, GTP, and

107 expression of the immunosuppressive ATP ecto-nucleotidase CD39.

108 the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP -> AMP) and CD73 (AMP -> ADO).

109 into adenosine (Ado) via two representative nucleotidases, CD39 and CD73.

110 In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating

111 llular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after thoracic

112 The cell surface nucleotidase CD73 is an immunosuppressive enzyme involve

113 es AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

114 The ecto-5'-nucleotidase CD73, an ectoenzyme highly expressed in can

115 ne, produced through the activity of ecto-5'-nucleotidase CD73, elicits potent immunosuppressive effe

116 mmunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

117 nosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

118 umulation of adenosine and increased ecto-5'-nucleotidase (CD73) and adenosine A(2B) receptor (ADORA2

119 "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhibitory f

120 tive channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

121 ed to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates surface a

122 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosphohydrol

123 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in extra

124 on of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrier f

125 ning, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive neurons an

126 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid body basal

127 Ecto-5'-nucleotidase (CD73) is a central surface enzyme generati

128 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for the pro

129 Ecto-5'-nucleotidase (CD73) is central to the generation of extr

130 Ecto-5'-nucleotidase (CD73) is expressed abundantly on the apica

131 Ecto-5'-nucleotidase (CD73) is the main enzyme responsible for t

132 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extracellular

133 m, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

134 Ecto-5'-nucleotidase (CD73) on immune cells is emerging as a cri

135 y response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart failure

136 to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

137 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in conjunctio

138 In contrast, a subset expressing Ecto-5'-nucleotidase (CD73) was retained and a specific CD73(+)N

139 (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to threefold

140 han in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

141 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts extracellul

142 e present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates adenosine,

143 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the major enzym

144 the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and organ func

145 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of extracell

146 Ecto-5'-nucleotidase (CD73), the enzyme that generates adenosine

147 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert ex

148 nophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contribution of CD7

149 of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly lower in C5

150 phosphate diphosphohydrolase 1 (CD39) and 5'-nucleotidase (CD73).

151 terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

152 sphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

153 k) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme responsible

154 ate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymph n

155 osphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 patien

156 and characterized a novel human cytosolic 5'-nucleotidase (cN-I) that potentially may have an importa

157 senger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchial

158 Two, cloned cytosolic 5'-nucleotidases (cN-I and cN-II) have been implicated in A

159 been identified as targeting cytoplasmic 5' nucleotidase (cN1A; NT5C1A), a protein involved in nucle

160 of substrates away from the enzymes, and 3) nucleotidase co-localization and the presence of complem

161 uggest that P2 nucleotide receptors and ecto-nucleotidases compete for a limited pool of endogenously

162 s related archaeal 20S proteasomes require a nucleotidase complex such as PAN to mediate the energy-d

163 With this model, we find that 1) nucleotidase confinement reduces reaction rates relative

164 This indicates that the 5'-nucleotidase contributes to but is not solely responsibl

165 ame time, surface-expressed ectoapyrases and nucleotidases convert extracellular nucleotides to adeno

166 urine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, purine nucleoside phosphoryla

167 The 5'-nucleotidase, cytosolic II gene (NT5C2, cN-II) is associ

168 of one of these hits, confirmed NT5C (5',3'-Nucleotidase, Cytosolic) as a novel AKT substrate, with

169 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-deficient

170 timuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A1-adenos

171 of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(+) T reg

172 the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphatase

173 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metall

174 duals, siRNA of tetraspanin 33 (TSPAN33), 5'-nucleotidase, ecto (NT5E), transmembrane emp24 protein t

175 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extr

176 cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

177 eotidase II gene (NT5C2), which encodes a 5'-nucleotidase enzyme that is responsible for the inactiva

178 Disruption of TG neuronal ecto-nucleotidase expression and axonal terminal localization

179 bset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence intensi

180 rong in salivary-expressed members of the 5'-nucleotidase family of arthropods because of constraints

181 Members of the 5'nucleotidase family were recruited for salivary expressi

182 while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

183 ineering the soluble human calcium-activated nucleotidase for clinical applications.

184 Here we describe a novel 5' nucleotidase from Drosophila that cleaves m(7)GMP to 7-m

185 d to the redistribution of syntaxin 2 and 5' nucleotidase from the apical membrane to subapical punct

186 Disruption of the yeast 3'-nucleotidase gene or treatment of cells with lithium res

187 Two SNPs at the 5'-nucleotidase gene were associated with NCPH: rs11191561

188 nucleotides, mammals possess two related 3'-nucleotidases, Golgi-resident 3'-phosphoadenosine 5'-pho

189 CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did not affe

190 However, inhibition of 5'-nucleotidase had no effect on ATP/ADP/UTP-induced phosph

191 HUVEC express NTPDases, as well as 5'-nucleotidase; hence, nucleotides can be metabolized to a

192 ign potential inhibitors of the cytosolic 5'-nucleotidase II (cN-II), which has been recognized as an

193 Activating mutations in cytosolic 5'-nucleotidase II (NT5C2) are considered to drive relapse

194 Mutations in the cytosolic 5' nucleotidase II (NT5C2) gene drive resistance to thiopur

195 ast to cNIII-like, cNIII and human cytosolic nucleotidase II do not accept m(7)GMP as a substrate.

196 g, we identify mutations in the cytosolic 5'-nucleotidase II gene (NT5C2), which encodes a 5'-nucleot

197 ABL1 fusions, NOTCH1/FBXW7, and cytosolic 5'-nucleotidase II gene mutations identify patient groups w

198 Cytosolic 5'-nucleotidase III (cN-III) is responsible for selective d

199 e similarity to two human enzymes, cytosolic nucleotidase III (cNIII) and the previously uncharacteri

200 and the previously uncharacterized cytosolic nucleotidase III-like (cNIII-like).

201 supported by comparison to YfdR, another 5'-nucleotidase in E. coli.

202 role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

203 anism for regulation of the activity of this nucleotidase in the physiological setting of the endopla

204 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog alpha,b

205 rectly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

206 previously unidentified gene, PTPN (PTP-like Nucleotidase) in plant drought tolerance.

207 a 2-step enzymatic reaction mediated by ecto-nucleotidases, including CD73 and ecto-nucleoside tripho

208 Both parasite secreted products and the 5'-nucleotidase inhibit ADP-induced release of mast cell pr

209 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene adenosine-5

210 inally, this response was potentiated by the nucleotidase inhibitor 6-N,N-diethyl-beta-gamma-dibromom

211 beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP prevent

212 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200 mic

213 s greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200 mic

214 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significantly dim

215 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellular ATP

216 enosine activity was clamped by combining 5'-nucleotidase inhibitor with A1-agonist to determine whet

217 sine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene adenosine 5

218 osine A1 receptor blocker, A1-agonist, or 5'-nucleotidase inhibitor.

219 transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine significantly

220 C infection by testing the effect of ecto-5'-nucleotidase inhibitors.

221 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosine, whic

222 adation of secreted ATP by ecto- and soluble nucleotidases is a possible explanation.

223 This family of nucleotidases is unrelated in sequence to more well-stud

224 e hexamer, whereas the proteasome-activating nucleotidase-like contact is required to close the ring.

225 the PO4 moieties from ATP, likely with a 5'-nucleotidase-like enzyme rather than alkaline phosphatas

226 hatases (CCAPs), which are nonspecific 5',3'-nucleotidases localized to the bacterial outer membrane.

227 Use of soluble 5'-nucleotidase may be a potential therapeutic for hepatic

228 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation from the

229 These vertebrate nucleotidases may play a role in protein glycosylation.

230 one proposed for the catalytic mechanisms of nucleotidase members of the haloacid dehalogenase family

231 degradation by diphosphohydrolases and ecto-nucleotidases (NDAs).

232 B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and highlig

233 at specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor activation

234 We show that presentation of Lm nucleotidase (NT)-OVA is TAP independent in vivo and in

235 ecreted chimeric protein with L. donovani 3' nucleotidase (NT-OVA).

236 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP to adeno

237 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in STP neu

238 CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by g

239 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored protein

240 )R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphatase

241 mulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, prostatic ac

242 ial P2Y receptors via expression of the ecto-nucleotidase NTPDase2.

243 Cell-surface nucleotidases (NTPDases) contain 10 invariant cysteine r

244 s unique, bi-functional, surface membrane 3'-nucleotidase/nuclease (Cl 3'NT/NU) activity by approxima

245 nly found in canonical proteasome-activating nucleotidases of the PAN/ARC/Rpt group, which are absent

246 lyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors were prote

247 ckade and reduced by apyrase inactivation of nucleotidases, P2 receptor antagonists, tetrodotoxin (TT

248 s stimulated using the proteasome-activating nucleotidase (PAN) ATPase complex.

249 ing of two H. volcanii proteasome-activating nucleotidase (PAN) genes (panA and panB).

250 anA and panB) encoding proteasome-activating nucleotidase (PAN) proteins closely related to the regul

251 ranslocases Hsp104 and proteasome-activating nucleotidase (PAN) to alleviate the toxicity from protei

252 with the AAA+ Cdc48 or proteasome-activating nucleotidase (PAN) unfoldases.

253 mohexameric complex of proteasome-activating nucleotidase (PAN), is responsible for target protein re

254 mohexameric complex of proteasome-activating nucleotidase (PAN).

255 d moiety of ubiquitin is a substrate for the nucleotidase/phosphohydrolase, resulting in either trans

256 polypeptide: an ADP-ribosyltransferase and a nucleotidase/phosphohydrolase.

257 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulating this

258 We suggest that the m(7)G-specific nucleotidases protect cells against undesired salvage of

259 ii encodes two related proteasome-activating nucleotidase proteins, PanA and PanB, with PanA levels p

260 target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors and metast

261 oteasomes and the PAN (proteasome-activating nucleotidase) regulatory complex, a homolog of the eukar

262 Thus, chronic administration of nucleotidase-resistant phosphonates conferred a benefici

263 structures of ClpX and proteasome-activating nucleotidase, respectively.

264 Intranasal instillations of exogenous nucleotidase restored the ability of lungs of CD73(-/-)

265 nstitution of cd73(-/-) mice with soluble 5'-nucleotidase resulted in complete restoration of hepatop

266 Inhibition of ecto-nucleotidases resulted in ATP accumulation at a rate of

267 Mutations in ushA, encoding a predicted 5'-nucleotidase, resulted in accumulation of flavin adenine

268 In addition, expression of the full-length nucleotidase revealed that this membrane-bound form can

269 karya or with the AAA+ proteasome-activating nucleotidase ring in some archaea.

270 rate of extracellular ATP hydrolysis by ecto-nucleotidase(s).

271 Like other 5'-nucleotidases, S5nA requires divalent cations and was ac

272 and metabotropic P2 receptors, exo- and ecto-nucleotidases, second messengers, and gap junctions.

273 ed a cell wall-anchored protein harbors a 5'-nucleotidase signature sequence and evidence strongly in

274 y facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

275 data indicate that the accumulation of a 3'-nucleotidase substrate, such as PAP, mediates the toxici

276 ype-1 (ENTPD1) is the dominant vascular ecto-nucleotidase that catalyzes the phosphohydrolysis of ext

277 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phosphohydrolys

278 y the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine introduced a

279 ce that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to test whe

280 CD73 is a cell surface 5'-nucleotidase that converts AMP to adenosine, an immune s

281 purinergic signaling are determined by ecto-nucleotidases that control ATP degradation and adenosine

282 ecrease in activity of Ca(2+)-dependent ecto-nucleotidases that degrade ATP.

283 s are regulated by anabolic processes and by nucleotidases that hydrolyse these metabolites into nucl

284 hese compounds have been well described, the nucleotidases that may mediate drug resistance through d

285 tly identified dimeric nature of the soluble nucleotidase, the dimer interface contains a central cor

286 ndothelial cell-specific molecule-1, 5'-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, e

287 Eukaryotic pyrimidine 5'-nucleotidase type 1 (P5N-1) catalyzes dephosphorylation

288 mals express a protein homologous to soluble nucleotidases used by blood-sucking insects to inhibit h

289 treatment of wild-type mice with soluble 5'-nucleotidase was associated with significantly lower lev

290 has been named PAN for proteasome-activating nucleotidase was characterized from the hyperthermophile

291 The secreted 5'-nucleotidase was identified as a protein with an apparen

292 nephropathy, whereas treatment with soluble nucleotidase was therapeutic.

293 ycophosphatidylinositol-anchored protein, 5'-nucleotidase, were observed, suggesting that increased m

294 s demonstrate that NBD1 of ABCR is a general nucleotidase, whereas NBD2 is a specific ATPase.

295 erase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, n

296 sphohydrolase (E-NTPDase 8) are cell surface nucleotidases with two transmembranous domains, one each

297 l function to be a nuclease, phosphatase, or nucleotidase, with a requirement for some metal ions.

298 in phosphohydrolase, the Escherichia coli 5'-nucleotidase YfbR.

299 s (ndk, pykA, or pykF) and the gene for a 5'-nucleotidase (yfbR).

300 The nucleotidase YjjG is critical for this step.